Categories: Health

Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease

TAINAN, June 13, 2025 /PRNewswire/ — Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer’s disease (AD). TML-6 combines multiple mechanisms, including anti-oxidative effects (Nrf2 activation), melioration of autophagy function (autolysosomal activation), anti-amyloid accumulation (β-amyloid clearance), and anti-inflammatory effects (through NF-κB inhibition) through autolysosome pathway in neurons and microglia to remove intraneuronal and extracellular amyloid accumulation, representing the first in human multi-target strategy for AD treatment.

- Advertisement -

The Phase I trial showed excellent safety, tolerability, and pharmacokinetics at 100–200 mg in both healthy and elderly adults. TML-6 will now advance to a Phase II 19 site trial across the United States, Sweden, and Taiwan after FDA approval. This 12-month study will enroll 210 patients with mild cognitive impairment (MCI) or mild dementia.

- Advertisement -

Primary endpoints will include neuropsychological assessments (CDR-SB, iADRS) and blood biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP), supported by brain MRI, amyloid PET scans, and ApoE genotyping. Type C FDA consultation for phase 2 trial design has completed on 13 May 2025, with trial initiation expected in April 2026, conducted by Syneos Health CRO.

With its strong preclinical and clinical profile, TML-6 holds promise as both a monotherapy and in combination with anti-amyloid biologics, providing new hope for patients with Alzheimer’s disease.

- Advertisement -

About Merry Life Biomedical Company

- Advertisement -

Merry Life Biomedical is a Taiwan-based biotechnology company focused on developing innovative therapies for neurodegenerative and age-related diseases. Leveraging advanced molecular design, pharmacological innovation, formulation optimization and global clinical development, the company is committed to addressing urgent unmet medical needs.

Media Contact
Dr. Ih-Jen Su
Merry Life Biomedical Company, Ltd.
Phone: +886-910-902-296
Email: suihjen0704@stust.edu.tw 

- Advertisement -

Logo – https://mma.prnewswire.com/media/2708243/Merry_Life_LOGO_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/merry-life-launches-global-phase-ii-trial-of-tml-6-the-first-drug-targeted-at-autolysosome-pathway-for-therapy-of-alzheimers-disease-302478755.html

PRNW Agency

Recent Posts

Medidata Secures a Leader Position in Everest Group’s PEAK Matrix Assessment for eCOA, Driving the New Patient Experience Forward

Medidata eCOA was the highest Leader recognized in the evaluation, supporting over 1M+ patients and…

4 hours ago

SEMI Reports Global Semiconductor Equipment Billings Increased 24% Year-Over-Year in Q2 2025

Strong Growth in the First Half of the Year Driven by Advanced Logic and DRAM…

4 hours ago

Salesforce Announces Quarterly Dividend

SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world’s #1 AI CRM, today announced that its board…

5 hours ago

Deok-ho Lim of NEL Animal Cardiovascular Center Delivers Keynote Speech at Jiangsu Province Pet Economic Development Conference

HUAIAN, China--(BUSINESS WIRE)--#2ndJiangsuProvincePetEconomicDevelopmentConference--Deok-ho Lim, director at SV Cross-border Group, a company specializing in the international…

5 hours ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

September 04, 2025 20:00 ET  | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and…

7 hours ago

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a…

7 hours ago